Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors

• Verfasst von: Hofheinz, Ralf-Dieter [VerfasserIn]
• Titel: Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors
• Verf.angabe: Ralf-Dieter Hofheinz, Siegfried Segaert, María José Safont, Gaston Demonty, Hans Prenen
• E-Jahr: 2017
• Jahr: 11 April 2017
• Umfang: 12 S.
• Fussnoten: Available online 11 April 2017 ; Gesehen am 15.08.2018
• Titel Quelle: Enthalten in: Critical reviews in oncology, hematology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1983
• Jahr Quelle: 2017
• Band/Heft Quelle: 114(2017), Seite 102-113
• ISSN Quelle: 1879-0461
• DOI: doi:10.1016/j.critrevonc.2017.03.032
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cetuximab
• Sach-SW: EGFR
• Sach-SW: Gastrointestinal cancer
• Sach-SW: Monoclonal antibodies
• Sach-SW: Panitumumab
• Sach-SW: TKIs
• Sach-SW: Toxicity
• K10plus-PPN: 1580053211

Abstract

The epidermal growth factor receptor (EGFR) is involved in development and progression of some gastrointestinal cancers, and is targeted by monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) used to treat these conditions. Targeted agents are generally better tolerated than conventional chemotherapy, but have characteristic toxicities that can affect adherence, dosing, and outcomes. Skin conditions are the most common toxicities associated with EGFR inhibitors, particularly papulopustular rash. Other common toxicities include mucosal toxicity, electrolyte imbalances (notably hypomagnesaemia), and diarrhoea, while the chimaeric mAb cetuximab is also associated with increased risk of infusion reactions. With appropriate prophylaxis, the incidence and severity of these events can be reduced, while management strategies tailored to the patient and the degree of toxicity can help to ensure continuation of anti-cancer therapy. Here, we review the main toxicities associated with EGFR-inhibiting mAbs and TKIs in patients with gastrointestinal cancers, and provide recommendations for prophylaxis and treatment.